Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator

FIRST COLLABORATIVE EFFORT UNDER NEW AGREEMENT

ALLEN, TX / ACCESSWIRE / September 18, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences, represented by Professor Tchorbanov PhD, Head of the Department of Immunology and Penka Petrova PHD, DSc, Director of the Institute of Microbiology, has issued its first report under the recently announced collaborative agreement executed on September 9, 2024. The purpose of the study, which was sponsored by Rosetta, LLC, was to ascertain any pathological deviations as a result of the use of ENZC's exclusively licensed experimental cancer lyophilized pepsin treatment's key active ingredient, Irreversible Pepsin Fraction ("IPF"), on the Kidney, Liver, Lymph Nodes and Spleen, measure the increased activation of the immune system, determine any side effects from the use of the compound and establish survivability of the animals (mouse model on Balb/c inbred mouse line under specific pathogen free sterile conditions) used in the study.

The sponsor of the study, Rosetta, LLC was awarded a licensing agreement by Zhabilov Trust for the production and distribution of IPF in spray form in the EU under the name Enzoimmune Active. ENZC will have the rights to North American markets.

The immunostimulatory testing consisted of a series of experiments to test IPF under In Vivo conditions for stimulation of specific clones of the immune system, as well as various pathophysiological indicators concerning the condition of the organs and evaluation of the survival of the treated animals with different regimes of the therapy making it possible to find the optimal conditions for treatment.

The results of the conducted experiments provided multifaceted information on the intimate mechanisms of activation and interaction between individual components of the immune system (humeral and cellular clone), as well as on interaction between innate and acquired immunity in general. One of the most significant findings was the increase in the amount of B- regulatory cells, a main factor for increased control over the functions of the immune system.

The report concludes, in summary, it can be said that IPF has a stimulating and modulating effect on the components of cell populations that make up innate and acquired immunity. The preparation activates a number of cohorts of B, T and NK cells, as well as macrophages. The regulatory elements are generates, as well as the synthesis of antibodies. There were no side effects or adverse reactions, with a 100% survival rate.